ArticleCellular and molecular gastroenterology and hepatology2026
Enteral Feeding With Omega-3 Polyunsaturated Fatty Acids Mitigates Liver Injury Following Massive Intestinal Resection.
Article in Cellular and molecular gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the Alpha and Omega: Redefining the Peroxisome Proliferator-Activated Receptor α Gut-Liver Axis in Intestinal Failure-Associated Liver Disease.Cellular and molecular gastroenterology and hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
BACKGROUND &
aimsIntestinal failure-associated liver disease results from massive small bowel resection (SBR). We assessed the impact of isocaloric enteral omega-3 (ω-3) and omega-6 (ω-6) polyunsaturated fatty acids (PUFAs) on intestinal function and liver injury following massive enterectomy.
methodsMale C57BL/6J mice underwent SBR or sham operation. Mice received either ω-3-enriched, ω-6-enriched, or a balanced saturated/monounsaturated/PUFA (control) diet postoperatively. At 10 weeks, body composition, metabolic profiles, intestinal adaptation, and liver injury were assessed. Targeted lipidomic profiling and bulk RNA sequencing of liver and intestine was completed. The role of Pparα activity was assessed in vivo by genetic deletion and pharmacologic activation.
resultsω-3-fed mice experienced improved weight recovery and more efficient energy metabolism following SBR. Compared with control mice, SBR mice fed either ω-3 or ω-6 diets showed reduced serum aspartate aminotransferase and alanine aminotransferase. Hepatic free fatty acid analysis reflected dietary intake. Hepatic steatosis and fibrosis was lowest in ω-3, intermediate in ω-6, and highest in control mice following SBR. Hepatic RNA sequencing found upregulation of fibrotic pathways in both the SBR control and SBR ω-6 with lipid metabolism upregulated in the SBR ω-3. Pparα was shown to be necessary for survival but not sufficient for hepatoprotection following SBR, which suggested that ω-3 fatty acids engage in Pparα-independent effects. RNA sequencing of the remnant ileum found ω-3 fatty acids promote upregulation of genes related to lipid metabolism and nutrient absorption consistent with a more proximal intestinal identity.
conclusionsThese data suggest that enteral feeding with ω-3 PUFAs improves intestinal functional adaptation and protects the liver injury after SBR while improving weight recovery and energy expenditure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.